News Releases

by Year

2009

Dec. 18, 2009 (PDF/46KB)Products

SEPRACOR GRANTED PATENT TERM EXTENSION FOR LUNESTA AND PROVIDES UPDATE ON LUNESTA PEDIATRIC STUDIES
Dec. 15, 2009 (PDF/52KB)Products

Notice of launching of therapeutic agent for hepatocellular carcinoma "MIRIPLA"
Nov. 27, 2009 (PDF/73KB)Related Business

Notice of Restructuring (Company Split) of the Company's Non-pharmaceutical Operations
Oct. 29, 2009 (PDF/189KB)Finances

Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2010 (Unaudited)
Oct. 29, 2009 (PDF/301KB)Finances

Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2010
Oct. 29, 2009 (PDF/78KB)Finances

Difference from Financial Forecasts for the Second Quarter of the Year Ending March 31, 2010 and Revision of Financial Forecasts for the Year Ending March 31, 2010
Oct. 21, 2009 (PDF/35KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc.
Oct. 16, 2009 (PDF/50KB)Products

Therapeutic agent for hepatocellular carcinoma "MIRIPLA" obtained manufacturing and marketing approval
Oct. 14, 2009 (PDF/45KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. Completes Tender Offer for Sepracor Inc.
Sep. 11, 2009 (PDF/65KB)Products

New OD tablet of AMLODIN by original formulation technology "SUITAB-NEX"
Sep. 03, 2009 (PDF/55KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. to Acquire U.S.-based Sepracor Inc.
Aug. 26, 2009 (PDF/92KB)R&D

LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY
Jul. 31, 2009 (PDF/367KB)Finances

Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2010
Jun. 26, 2009 (PDF/40KB)Corporate

Announcement of establishment of a holding company in the U.S.
Jun. 19, 2009 (PDF/57KB)Products

Acquisition of an additional indication of AmBisome, a therapeutic agent for systemic fungal infection
Jun. 03, 2009 (PDF/88KB)R&D

STUDY DEMONSTRATING LURASIDONE IS EFFECTIVE IN PATIENTS WITH SCHIZOPHRENIA PUBLISHED IN THE JOURNAL OF CLINICAL PSYCHIATRY
May 21, 2009 (PDF/106KB)R&D

DAINIPPON SUMITOMO PHARMA ANNOUNCES LURASIDONE PHASE III DATA IN PATIENTS WITH SCHIZOPHRENIA
May 11, 2009 (PDF/194KB)Finances

Summary of Consolidated Financial Results for the Year Ended March 31, 2009 (Unaudited)
May 11, 2009 (PDF/291KB)Finances

Supplementary Financial Data For the Year Ended March 31, 2009
Apr. 22, 2009 (PDF/62KB)Products

Acquisition of an additional indication relating to pretreatment for barium enema X-ray examination by concomitant use of NIFLEC and GASMOTIN
Apr. 17, 2009 (PDF/36KB)R&D

Discontinuation of development of AC-3933, a therapeutic agent for dementia
Apr. 09, 2009 (PDF/39KB)Corporate

Wakunaga appealed to the Supreme Court against the Osaka High Court's decision
Mar. 24, 2009 (PDF/40KB)Corporate

Announcement of a judgment of the suit (an appeal court decision)
Mar. 16, 2009 (PDF/52KB)Related Business

Launch of "PRONAMID",a gastro-prokinetic agent for dogs
Mar. 13, 2009 (PDF/75KB)Products

Notice of launching of a new Parkinson's disease drug "TRERIEF"
Feb. 03, 2009 (PDF/325KB)Finances

Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2009
Jan. 21, 2009 (PDF/49KB)Products

Parkinson's disease drug "TRERIEF" obtained manufacturing and marketing approval